Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria may hold key to cancer risk in lynch syndrome

NCT ID NCT02371135

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how bacteria living in the gut and diet might influence colorectal cancer risk in people with Lynch syndrome and other inherited colon conditions. Researchers will collect stool samples, colon biopsies, and diet questionnaires from 77 participants during routine colonoscopies. The goal is to better understand the link between gut microbes, diet, and cancer risk in these high-risk groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify dietary or bacterial factors that lower colorectal cancer risk in people with inherited syndromes.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not lead to direct clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

77 people

The number who actually took part.

Started

Feb 2015

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Potential research subjects will be identified prospectively within the clinics of the Clinical Genetics and Gastroenterology Services, of MSKCC.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female age 18 or older * Hereditary colorectal cancer syndrome with one of the following: * Lynch syndrome, as defined by the presence of a deleterious germline mutation in the MLH1, MSH2, MSH6, PMS2 or EPCAM genes * Other hereditary colonic polyposis syndromes, as defined by the presence of a deleterious germline mutation in any one of the following polyposis genes (APC, biallelic MYH, STK11, SMAD4, BMPR1A, or other CRC-risk associated genes at discretion of PI) Exclusion Criteria: * Unable to provide informed consent for testing * Unable to complete English language questionnaire * Receiving active chemotherapy * Having completed active chemotherapy less then 12 months prior to day of scheduled lower endoscopy * No infectious or drug induced colitis less then 12 months prior to day of scheduled lower endoscopy * No history of inflammatory colitis (Crohn's disease or ulcerative colitis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary colonic polyposis syndromes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis intestinal polyposis syndrome Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary colonic polyposis syndromes Lynch syndrome

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.